-
公开(公告)号：EP3174546B1
公开(公告)日：2019-10-30
申请号：EP15753252.4
申请日：2015-07-31
IPC分类号： C07K16/28 , A61K39/00 , A61K35/17 , C07K14/705 , A61K39/395 , A61K31/436 , C07K14/725 , C12N5/0783
-
公开(公告)号：EP3174546A1
公开(公告)日：2017-06-07
申请号：EP15753252.4
申请日：2015-07-31
IPC分类号： A61K35/17 , C07K14/705
摘要： This disclosure provides, for instance subset-optimized CART cells and related methods. For instance, the disclosure describes methods and compositions of CD4′ and CD8′ T cells that express CARs containing specific combinations of intracellular signaling domains can be used to increase persistence and anti-tumor activity of the infused CAR-expressing T cells for treating a subject having a disease, e.g., a cancer.
摘要翻译： 本公开提供了例如子集优化的CART单元和相关方法。 例如，本公开内容描述了表达CAR的CD4 +和CD8 + T细胞的方法和组合物，其中含有细胞内信号传导结构域的特定组合可用于增加注入的表达CAR的T细胞的持久性和抗肿瘤活性，用于治疗患有 疾病，例如癌症。
-
3.发明公开
公开(公告)号：EP4303229A2
公开(公告)日：2024-01-10
申请号：EP23193480.3
申请日：2015-01-21
IPC分类号： C07K14/705
摘要： The invention provides T cells comprising nucleic caid sequence encoding a chimeric antigen receptor and a nucleic acid sequenceencoding an enhancer of T cell priming, compositions including the T cells, and methods of using the T cells to treat diseases associated with the expression of disease-associated antigens.
-
公开(公告)号：EP4036109A2
公开(公告)日：2022-08-03
申请号：EP21209515.2
申请日：2015-12-28
发明人： BEDOYA, Felipe , GHASSEMI, Saba , JUNE, Carl H. , LEVINE, Bruce L. , MELENHORST, Jan J. , MILONE, Michael C. , POWELL, Daniel J. Jr. , ZHENG, Zoe
IPC分类号： C07K14/725 , C12N5/00 , C12N5/0783 , A61K39/00
摘要： The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), and compositions and reaction mixtures comprising the same.
-
公开(公告)号：EP3967709A1
公开(公告)日：2022-03-16
申请号：EP21183416.3
申请日：2015-09-17
发明人： ENGELS, Boris , IDAMAKANTI, Neeraja , JUNE, Carl H. , LOEW, Andreas , MILONE, Michael C. , ENGELS, Boris , WANG, Enxiu , WU, Qilong , BEATTY, Gregory
IPC分类号： C07K16/28 , C07K16/30 , C07K14/705 , C07K14/735 , A61P35/00 , A61P37/04 , A61P43/00
摘要： The present invention provides compositions and methods for regulating the specificity and activity of immune effector cells for use in immunotherapy. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a "NKR-CAR" which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).
-
公开(公告)号：EP4406610A3
公开(公告)日：2024-10-30
申请号：EP24166976.1
申请日：2015-04-07
发明人： BYRD, John , DUBOVSKY, Jason , FRAIETTA, Joseph , GILL, Saar , GLASS, David , JOHNSON, Amy , JUNE, Carl H. , KENDERIAN, Saad , MANNICK, Joan , MAUS, Marcela , MURPHY, Leon , MUTHUSAMY, Natarajan , PORTER, David L. , RUELLA, Marco , SELLERS, William Raj , WASIK, Mariusz , BROGDON, Jennifer
IPC分类号： A61K39/00 , A61K35/17 , A61K31/436 , A61P35/02
摘要： The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein. The invention also provides kits and compositions described herein.
-
公开(公告)号：EP4205749A1
公开(公告)日：2023-07-05
申请号：EP22210490.3
申请日：2015-07-31
IPC分类号： A61K35/17 , C07K14/705 , A61K31/436 , A61K39/00 , A61K39/395 , C07K14/725 , C07K16/28 , C12N5/0783
摘要： This disclosure provides, for instance subset-optimized CART cells and related methods. For instance, the disclosure describes methods and compositions of CD4 + and CD8 + T cells that express CARs containing specific combinations of intracellular signaling domains can be used to increase persistence and anti-tumor activity of the infused CAR-expressing T cells for treating a subject having a disease, e.g., a cancer.
-
8.发明公开
公开(公告)号：EP3172237A2
公开(公告)日：2017-05-31
申请号：EP15753519.6
申请日：2015-07-21
发明人： BROGDON, Jennifer , CHOI, Eugene , EBERSBACH, Hilmar , GLASS, David , HUET, Heather , JUNE, Carl H. , MANNICK, Joan , MILONE, Michael C. , MURPHY, Leon , PLESA, Gabriela , RICHARDSON, Celeste , RUELLA, Marco , SINGH, Reshma , WANG, Yongqiang , WU, Qilong
CPC分类号： C07K14/705 , A61K35/12 , A61K38/177 , C07K16/2878 , C07K2317/24 , C07K2317/565 , C07K2317/622 , C07K2317/92 , C07K2319/00 , C07K2319/30
摘要： The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.
摘要翻译： 本发明提供了用于治疗与BCMA表达相关的疾病的组合物和方法。 本发明还涉及对编码BCMA载体的BCMA载体特异性的嵌合抗原受体（CAR）和包含BCMA CAR的重组T细胞。 本发明还包括施用表达包含BCMA结合结构域的CAR的遗传修饰的T细胞的方法。
-
公开(公告)号：EP4036109A3
公开(公告)日：2022-10-12
申请号：EP21209515.2
申请日：2015-12-28
发明人： BEDOYA, Felipe , GHASSEMI, Saba , JUNE, Carl H. , LEVINE, Bruce L. , MELENHORST, Jan J. , MILONE, Michael C. , POWELL, Daniel J. Jr. , ZHENG, Zoe
IPC分类号： C07K14/725 , C12N5/00 , C12N5/0783 , A61K39/00
摘要： The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), and compositions and reaction mixtures comprising the same.
-
10.发明公开
公开(公告)号：EP4056588A1
公开(公告)日：2022-09-14
申请号：EP22162298.8
申请日：2016-04-08
发明人： BITTER, Hans , BORDEAUX, Jennifer Mary , BRANNETTI, Barbara , BROGDON, Jennifer , DAKAPPAGARI, Naveen Kumar , GILL, Saar , HIGHFILL, Steven , HUANG, Lu , JUNE, Carl H. , KIM, Ju Young , LEI, Ming , LI, Na , LOEW, Andreas , ORLANDO, Elena , RUELLA, Marco , TRAN, Thai , ZHANG, Jimin , ZHOU, Li
IPC分类号： C07K14/725 , C07K16/28 , C12N5/0783 , A61K39/00
摘要： The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with one or more B-cell inhibitors, e.g., inhibitors of one or more of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. The disclosure additionally features novel antigen binding domains and CAR molecules directed to CD20 and CD22, and uses, e.g., as monotherapies or in combination therapies. The invention also provides kits and compositions described herein.
-
-
-
-
-
-
-
-
-
搜索结果
58 条记录 (耗时 0.036 秒)
